Lower rates of French health care reimbursement which took effect in August 1993 under France's Veil plan yielded economies of almost 2 billion french francs ($368.5 million) last year, says the national health fund, the CNAM.
The plan explains the slight slowdown in overall health care spending growth, which rose 5.7% last year compared to 7.1% in 1992, says data from the accounts commission. However, while the CNAM confirms a tendency for spending to slow down, this does not apply to the drug sector as a whole, where spending went up 7.5% last year against 7.4% in 1992.
It says 1993's savings include 859 million francs ($160.2 million) on medical fees, 1.1 billion francs on prescriptions and 30 million francs on other spending. This calculation takes account only of the 5% drop in reimbursement of drugs and medical fees, and not the rise in hospital day-rates, but shows that without the Veil measures, reimbursement outside the hospital sector would have risen 5% in 1993 instead of 4.1%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze